Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · IEX Real-Time Price · USD
10.02
+0.18 (1.83%)
Sep 27, 2022 4:00 PM EDT - Market closed
1.83%
Market Cap 669.16M
Revenue (ttm) 52.39M
Net Income (ttm) -101.48M
Shares Out 66.78M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE 7.18
Dividend n/a
Ex-Dividend Date n/a
Volume 502,273
Open 9.86
Previous Close 9.84
Day's Range 9.80 - 10.08
52-Week Range 7.18 - 13.17
Beta 0.66
Analysts Buy
Price Target 10.78 (+7.6%)
Earnings Date Nov 1, 2022

About TBPH

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as fo... [Read more...]

Industry Pharmaceuticals
CEO Rick Winningham
Employees 158
Stock Exchange NASDAQ
Ticker Symbol TBPH
Full Company Profile

Financial Performance

In 2021, TBPH's revenue was $55.31 million, a decrease of -23.03% compared to the previous year's $71.86 million. Losses were -$199.43 million, -28.27% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is 10.78, which is an increase of 7.58% from the latest price.

Price Target
$10.78
(7.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Theravance Biopharma plans $250 million capital return program

Theravance Biopharma Inc. TBPH, +0.20% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61% . The company will pur...

1 week ago - Market Watch

Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program

The Company has agreed to purchase GSK's entire holdings at $9.75 per share The Company plans to launch a Dutch auction tender offer in the near term to purchase approximately $95 million of its ordinar...

1 week ago - PRNewsWire

Theravance Biopharma to Present at Upcoming Investor Conferences

DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be we...

3 weeks ago - PRNewsWire

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

1 month ago - Zacks Investment Research

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA fil...

Other symbols: RPRX
1 month ago - PRNewsWire

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, Augus...

1 month ago - PRNewsWire

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

DUBLIN , July 26, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a tender offer (the "Offer") to purchase any and all of its out...

2 months ago - PRNewsWire

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva?

2 months ago - Zacks Investment Research

Theravance sets up deal to sell rights to asthma drug to Royalty Pharma

Shares of Theravance Biopharma Inc. TBPH, -0.80% were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's GSK, -1.25% Tre...

Other symbols: RPRX
2 months ago - Market Watch

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide ne...

Other symbols: INVA
2 months ago - Benzinga

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Up...

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of ...

Other symbols: RPRX
2 months ago - PRNewsWire

Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?

Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

4 months ago - Zacks Investment Research

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Implied 35% share of YUPELRI® (revefenacin) net sales1 : $15.3M Q1 2022 up 19% from Q1 2021 TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212 Results from a Phase 3 study of ampreloxetine sh...

4 months ago - PRNewsWire

Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022

DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2...

4 months ago - PRNewsWire

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Theravance Biopharma to Participate in an Upcoming Investor Conference

DUBLIN , April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET (10:30 am PT/...

5 months ago - PRNewsWire

Theravance's (TBPH) Hypotension Study Misses Primary Goal

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

5 months ago - Zacks Investment Research

Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's

Theravance Biopharma Inc (NASDAQ: TBPH) revealed results from the second Phase 3 study assessing ampreloxetine compared to placebo for symptomatic nOH.  Neurogenic orthostatic hypotension (nOH) is a rar...

5 months ago - Benzinga

Why Theravance Biopharma Stock Is Trading Lower After Hours

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistically...

5 months ago - Benzinga

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients wi...

Results from Study 0170 show a benefit in study patients with multiple system atrophy (MSA) Company beginning discussions with potential strategic partners and planning health authority interactions to ...

5 months ago - PRNewsWire

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research